Ozempic and depression: what the evidence actually shows

Based on the current evidence, there is no established causal link. Both the US FDA and Europe's EMA reviewed reports of suicidal thoughts with GLP-1 medications and did not find that the drugs cause them. The FDA's comprehensive review — covering 91 placebo-controlled trials and more than 107,000 patients — found no increased risk, and in January 2026 the FDA asked manufacturers to remove the suicidal-behavior warning from the weight-management labels. The largest real-world study actually found a lower rate of suicidal ideation among semaglutide users than comparators. That said, anyone with a history of depression should be monitored, and mood changes always deserve attention.

The FDA first flagged reports and, in a January 2024 preliminary evaluation, said its review "did not show" a causal link but that it could not fully rule out a small risk, so it kept monitoring. After a comprehensive review of 91 placebo-controlled trials and 107,910 patients, in January 2026 the FDA concluded there was no increased risk of suicidal thoughts or behavior and requested that the warning be removed from Wegovy, Saxenda, and Zepbound. Separately, the EMA's safety committee (PRAC) concluded in April 2024 that the available evidence does not support a causal association. Two major regulators, independently, reached the same reassuring conclusion.

The concern was legitimate to investigate. Analyses of spontaneous adverse-event reporting databases flagged a statistical "signal" for suicidal ideation with some GLP-1 medications, and there were individual case reports. Importantly, a reporting signal shows that reports clustered — not that the drug caused the events; reporting is influenced by media attention and how widely a drug is used. Regulators took the signal seriously, ran comprehensive reviews of the controlled trial and real-world data, and did not find a causal link. That is the system working as intended.

No — and this is a common point of confusion because the same molecule has two labels. Ozempic (semaglutide for type 2 diabetes) never carried a depression or suicidal-thoughts warning. The higher-dose weight-management versions — Wegovy (semaglutide) and Saxenda (liraglutide) — historically instructed clinicians to monitor for depression or suicidal thoughts, a legacy of older obesity-drug labeling. In January 2026 the FDA requested that this warning be removed from those labels following its review. So a "Wegovy label warning" should not be attributed to Ozempic.

The evidence is reassuring, but sensible caution still applies. If you have a history of depression, anxiety, or suicidal thoughts, tell your prescriber before and during treatment so your mood can be monitored. Big life changes and rapid weight loss can affect mood on their own, independent of any drug. If you notice new or worsening depression, hopelessness, or thoughts of harming yourself, contact your clinician right away — and in the US you can call or text 988 (Suicide and Crisis Lifeline) any time. This page is general information, not a substitute for professional care.